2020 Q3 Form 10-Q Financial Statement
#000156459020049691 Filed on November 02, 2020
Income Statement
| Concept | 2020 Q3 | 2019 Q3 |
|---|---|---|
| Revenue | $12.45M | $16.00M |
| YoY Change | -22.2% | 16.47% |
| Cost Of Revenue | $2.657M | $4.192M |
| YoY Change | -36.62% | 38.17% |
| Gross Profit | $9.791M | $11.81M |
| YoY Change | -17.08% | 10.32% |
| Gross Profit Margin | 78.66% | 73.8% |
| Selling, General & Admin | $10.26M | $14.65M |
| YoY Change | -29.93% | 13.45% |
| % of Gross Profit | 104.82% | 124.04% |
| Research & Development | $1.952M | $3.489M |
| YoY Change | -44.05% | 64.19% |
| % of Gross Profit | 19.94% | 29.55% |
| Depreciation & Amortization | $210.0K | $310.0K |
| YoY Change | -32.26% | 47.62% |
| % of Gross Profit | 2.14% | 2.63% |
| Operating Expenses | $12.22M | $18.14M |
| YoY Change | -32.65% | 20.63% |
| Operating Profit | -$2.424M | -$6.328M |
| YoY Change | -61.69% | 46.08% |
| Interest Expense | $1.002M | $930.0K |
| YoY Change | 7.74% | 0.22% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $8.000K | $391.0K |
| YoY Change | -97.95% | 30.77% |
| Pretax Income | -$3.420M | -$6.870M |
| YoY Change | -50.22% | 38.51% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$3.418M | -$6.867M |
| YoY Change | -50.23% | 38.42% |
| Net Earnings / Revenue | -27.46% | -42.92% |
| Basic Earnings Per Share | -$0.18 | |
| Diluted Earnings Per Share | -$0.18 | -$371.2K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 18.89M | |
| Diluted Shares Outstanding | 18.89M |
Balance Sheet
| Concept | 2020 Q3 | 2019 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $50.70M | $82.40M |
| YoY Change | -38.47% | -22.85% |
| Cash & Equivalents | $50.70M | $82.37M |
| Short-Term Investments | ||
| Other Short-Term Assets | $3.500M | $2.400M |
| YoY Change | 45.83% | 14.29% |
| Inventory | $3.800M | $2.900M |
| Prepaid Expenses | $442.0K | |
| Receivables | $5.564M | $7.600M |
| Other Receivables | $1.600M | $600.0K |
| Total Short-Term Assets | $65.20M | $95.91M |
| YoY Change | -32.02% | -17.85% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $787.0K | $1.007M |
| YoY Change | -21.85% | -25.02% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $6.600M | $1.083M |
| YoY Change | 509.42% | 20.74% |
| Total Long-Term Assets | $13.10M | $9.575M |
| YoY Change | 36.81% | 327.46% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $65.20M | $95.91M |
| Total Long-Term Assets | $13.10M | $9.575M |
| Total Assets | $78.30M | $105.5M |
| YoY Change | -25.77% | -11.34% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.400M | $4.109M |
| YoY Change | -41.59% | 95.48% |
| Accrued Expenses | $6.171M | $7.612M |
| YoY Change | -18.93% | 19.25% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $34.54M | $7.500M |
| YoY Change | 360.56% | 50.0% |
| Total Short-Term Liabilities | $45.80M | $22.00M |
| YoY Change | 108.16% | 43.82% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $23.45M |
| YoY Change | -100.0% | -6.94% |
| Other Long-Term Liabilities | $5.100M | $5.700M |
| YoY Change | -10.53% | 171.43% |
| Total Long-Term Liabilities | $5.100M | $23.45M |
| YoY Change | -78.25% | -6.94% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $45.80M | $22.00M |
| Total Long-Term Liabilities | $5.100M | $23.45M |
| Total Liabilities | $50.90M | $51.15M |
| YoY Change | -0.49% | 19.99% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$273.9M | -$242.5M |
| YoY Change | 12.93% | |
| Common Stock | $296.9M | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $27.48M | $54.33M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $78.30M | $105.5M |
| YoY Change | -25.77% | -11.36% |
Cashflow Statement
| Concept | 2020 Q3 | 2019 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$3.418M | -$6.867M |
| YoY Change | -50.23% | 38.42% |
| Depreciation, Depletion And Amortization | $210.0K | $310.0K |
| YoY Change | -32.26% | 47.62% |
| Cash From Operating Activities | -$3.560M | -$7.660M |
| YoY Change | -53.52% | 55.69% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$140.0K | -$50.00K |
| YoY Change | 180.0% | -64.29% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | -$140.0K | -$50.00K |
| YoY Change | 180.0% | -64.29% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 410.0K | 440.0K |
| YoY Change | -6.82% | -99.55% |
| NET CHANGE | ||
| Cash From Operating Activities | -3.560M | -7.660M |
| Cash From Investing Activities | -140.0K | -50.00K |
| Cash From Financing Activities | 410.0K | 440.0K |
| Net Change In Cash | -3.290M | -7.270M |
| YoY Change | -54.75% | -107.88% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$3.560M | -$7.660M |
| Capital Expenditures | -$140.0K | -$50.00K |
| Free Cash Flow | -$3.420M | -$7.610M |
| YoY Change | -55.06% | 59.21% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P1Y | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P1Y | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P1Y | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P1Y | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P1Y | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P1Y | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y1M6D | ||
| CY2019Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
443000 | |
| CY2019Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
935000 | |
| CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6867000 | |
| CY2019Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
54330000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
48000 | |
| CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
646000 | |
| CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7765000 | |
| CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
29440000 | |
| CY2020Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
410000 | |
| CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1046000 | |
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3418000 | |
| CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
27478000 | |
| us-gaap |
Profit Loss
ProfitLoss
|
-23796000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-21490000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
741000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
765000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2888000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2458000 | ||
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
1113000 | ||
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
555000 | ||
| stim |
Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
|
150000 | ||
| stim |
Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
|
144000 | ||
| stim |
Non Cash Gains Losses On Extinguishment Of Debt
NonCashGainsLossesOnExtinguishmentOfDebt
|
-622000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-1005000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1933000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1004000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
455000 | ||
| stim |
Increase Decrease In Net Investment In Sales Type Leases
IncreaseDecreaseInNetInvestmentInSalesTypeLeases
|
1271000 | ||
| stim |
Increase Decrease In Net Investment In Sales Type Leases
IncreaseDecreaseInNetInvestmentInSalesTypeLeases
|
1774000 | ||
| stim |
Increase Decrease In Leasehold Reimbursement
IncreaseDecreaseInLeaseholdReimbursement
|
-875000 | ||
| stim |
Increase Decrease In Prepaid Commission Expense
IncreaseDecreaseInPrepaidCommissionExpense
|
1070000 | ||
| stim |
Increase Decrease In Prepaid Commission Expense
IncreaseDecreaseInPrepaidCommissionExpense
|
2907000 | ||
| us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
1263000 | ||
| us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-183000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2340000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
10000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-2981000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
80000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-356000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
285000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-26687000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-24079000 | ||
| us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
615000 | ||
| us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
454000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-615000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-454000 | ||
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
41360000 | ||
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
38860000 | ||
| us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
721000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
534000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2320000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2313000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2320000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-24989000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-22213000 | ||
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
75708000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
104583000 | |
| CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
50719000 | |
| CY2019Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82370000 | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
3060000 | ||
| us-gaap |
Interest Paid Net
InterestPaidNet
|
2240000 | ||
| stim |
Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
|
37000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
83000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
31000 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:4pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p id="N1_DESCRIPTION_BUSINESS" style="margin-bottom:0pt;margin-top:4pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>DESCRIPTION OF BUSINESS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neuronetics, Inc., or the Company, is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The Company’s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system was cleared in 2008 by the United States Food and Drug Administration, or the FDA, to treat adult patients with major depressive disorder, or MDD, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar Advanced Therapy is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COVID-19</p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is monitoring the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will impact the Company’s customers, supply chain, employees and other business partners. While the Company began to experience significant disruptions in March 2020 through the end of September 2020, from the COVID-19 pandemic, it is unable to predict the full impact that the COVID-19 pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. The outbreak of COVID-19 in many countries, including the United States, has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets.</p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applied for and received a $6.4 million loan in April 2020 under the Paycheck Protection Program (the “PPP”) established by the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) on March 27, 2020. Due to questions concerning the eligibility of public companies similarly situated to the Company, on May 7, 2020, the Company repaid the loan in full, including interest accrued to date.</p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, the Company had cash and cash equivalents of $50.7 million and an accumulated deficit of $273.9 million. The Company incurred negative cash flows from operating activities of $30.5 million for the year ended December 31, 2019 and $26.7 million for the nine months ended September 30, 2020. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company continues to invest in sales, marketing and product development activities. The Company’s primary sources of capital to date have been proceeds from its IPO, private placements of its convertible preferred securities, borrowings under its credit facilities and revenues from sales of its products. As of September 30, 2020, the Company had $35.0 million of borrowings outstanding under its credit facility, which has a final maturity in February 2025. As discussed in Note 12, the outstanding balance under the credit facility is classified as a current liability as of September 30, 2020. Management believes that the Company’s cash and cash equivalents and anticipated revenues from sales of its products are sufficient to fund the Company’s operations (including the potential repayment of the credit facility if a waiver or amendment is not obtained) for at least 12 months from the issuance of these financial statements. </p> | ||
| CY2020Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
50700000 | |
| CY2020Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-273900000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-30500000 | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-26700000 | ||
| us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>BASIS OF PRESENTATION </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, promulgated by the Financial Accounting Standards Board, or FASB. </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interim Financial Statements </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission, or SEC, which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets and statements of operations and stockholders’ deficit and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of operations and cash flows for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company’s Form 10-K filed with the SEC on March 3, 2020, wherein a more complete discussion of significant accounting policies and certain other information can be found. </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.</p> | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.</p> | ||
| CY2020Q3 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
6620000 | |
| CY2019Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
7117000 | |
| CY2020Q3 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
1056000 | |
| CY2019Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
548000 | |
| CY2020Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5564000 | |
| CY2019Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
6569000 | |
| CY2020Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3132000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3314000 | |
| CY2020Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2345000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2207000 | |
| CY2020Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
787000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1107000 | |
| CY2020Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
200000 | |
| CY2019Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
300000 | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
700000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
800000 | ||
| us-gaap |
Lessee Finance Lease Lease Not Yet Commenced Description
LesseeFinanceLeaseLeaseNotYetCommencedDescription
|
The Company does not currently have any finance leases or executed leases that have not yet commenced. | ||
| CY2020Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
200000 | |
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
200000 | ||
| CY2019Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
500000 | |
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
500000 | ||
| CY2020Q3 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y3M18D | |
| CY2020Q3 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.065 | |
| CY2020Q1 | stim |
Reimbursement Of Leasehold Expenses
ReimbursementOfLeaseholdExpenses
|
800000 | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
575000 | ||
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
330000 | ||
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
4164000 | ||
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
148000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
616000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
641000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
637000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
646000 | |
| CY2020Q3 | stim |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
2147000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
4835000 | |
| CY2020Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1033000 | |
| CY2020Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
3802000 | |
| CY2020Q3 | us-gaap |
Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
|
81000 | |
| CY2019Q3 | us-gaap |
Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
|
506000 | |
| us-gaap |
Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
|
807000 | ||
| us-gaap |
Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
|
768000 | ||
| CY2020Q3 | us-gaap |
Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
|
81000 | |
| CY2019Q3 | us-gaap |
Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
|
506000 | |
| us-gaap |
Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
|
807000 | ||
| us-gaap |
Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
|
768000 | ||
| CY2020Q3 | us-gaap |
Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Remainder Of Fiscal Year
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear
|
406000 | |
| CY2020Q3 | us-gaap |
Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
|
1624000 | |
| CY2020Q3 | us-gaap |
Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
|
1420000 | |
| CY2020Q3 | us-gaap |
Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
|
431000 | |
| CY2020Q3 | us-gaap |
Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
|
3881000 | |
| CY2020Q3 | us-gaap |
Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
|
3900000 | |
| CY2020Q3 | us-gaap |
Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
|
0 | |
| CY2020Q3 | us-gaap |
Operating Lease Lease Income
OperatingLeaseLeaseIncome
|
100000 | |
| CY2019Q3 | us-gaap |
Operating Lease Lease Income
OperatingLeaseLeaseIncome
|
200000 | |
| us-gaap |
Operating Lease Lease Income
OperatingLeaseLeaseIncome
|
200000 | ||
| us-gaap |
Operating Lease Lease Income
OperatingLeaseLeaseIncome
|
600000 | ||
| CY2020Q3 | us-gaap |
Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
|
261000 | |
| CY2020Q3 | us-gaap |
Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
|
150000 | |
| CY2020Q3 | us-gaap |
Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
|
411000 | |
| CY2019Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
560000 | |
| CY2020Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6171000 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9031000 | |
| stim |
Amortization Period Of Deferred Sales Commissions
AmortizationPeriodOfDeferredSalesCommissions
|
P7Y | ||
| CY2020Q3 | us-gaap |
Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
|
200000 | |
| CY2019Q3 | us-gaap |
Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
|
100000 | |
| us-gaap |
Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
|
600000 | ||
| us-gaap |
Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
|
200000 | ||
| CY2020Q3 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
3704000 | |
| CY2019Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
5724000 | |
| CY2020Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
396000 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
373000 | |
| CY2020Q3 | stim |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
574000 | |
| CY2019Q4 | stim |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
674000 | |
| CY2020Q3 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
43000 | |
| CY2019Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
127000 | |
| CY2020Q3 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
434000 | |
| CY2019Q4 | us-gaap |
Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
|
639000 | |
| CY2020Q3 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
586000 | |
| CY2019Q4 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
700000 | |
| CY2019Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
234000 | |
| CY2020Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
434000 | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
|
0.25 | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
|
0.29 | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
|
0.14 | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
|
0.14 | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
|
0.14 | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
|
0.04 | |
| CY2020Q3 | us-gaap |
Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
|
1 | |
| CY2020Q3 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
400000 | |
| us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
1700000 | ||
| CY2020Q3 | stim |
Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
|
1 | |
| stim |
Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
|
1 | ||
| CY2019Q3 | stim |
Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
|
0 | |
| stim |
Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
|
1 | ||
| CY2020Q3 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
35000000 | |
| CY2019Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
30000000 | |
| CY2020Q3 | stim |
Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
|
1925000 | |
| CY2019Q4 | stim |
Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
|
1838000 | |
| CY2020Q3 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
2383000 | |
| CY2019Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
690000 | |
| CY2020Q3 | us-gaap |
Long Term Debt
LongTermDebt
|
34542000 | |
| CY2019Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
31148000 | |
| CY2020Q3 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
34542000 | |
| CY2019Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
11250000 | |
| CY2019Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
19898000 | |
| CY2019Q3 | us-gaap |
Interest Expense Borrowings
InterestExpenseBorrowings
|
900000 | |
| CY2019Q3 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
700000 | |
| CY2019Q3 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
200000 | |
| us-gaap |
Interest Expense Borrowings
InterestExpenseBorrowings
|
3500000 | ||
| us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
3100000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
400000 | ||
| us-gaap |
Interest Expense Borrowings
InterestExpenseBorrowings
|
2800000 | ||
| us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
2200000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
600000 | ||
| CY2020Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18959000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18645000 | |
| CY2020Q3 | stim |
Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
|
25970000 | |
| CY2019Q4 | stim |
Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
|
23046000 | |
| CY2020Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
105000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2888000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2458000 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.02 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
400000 | ||
| stim |
Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Grant Date Fair Value Of Underlying Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageGrantDateFairValueOfUnderlyingCommonStock
|
2.01 | ||
| CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
2.01 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0038 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
|
0.553 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 |
